SCHEMBL954118

SCHEMBL954118

CCOC(=O)c1cccc2cccc(Br)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.58
CDC25B P30305 2/20 0.54
ALDH1A1 P00352 2/20 0.50
CDC25A P30304 1/20 0.50
CDC25C P30307 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CYP1A2 P05177 2/20 0.49
CNR2 P34972 4/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK10 P53779 1/20 0.47
KMT2A Q03164 1/20 0.47
PTK2B Q14289 1/20 0.47
NCOA1 Q15788 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3681837 0.88 TSHR (0.68) TSHRCDC25BALDH1A1CDC25ACDC25C
SCHEMBL18526159 0.86 TSHR (0.66) TSHRCDC25BALDH1A1CDC25ACDC25C
SCHEMBL21845577 0.83 TSHR (0.61) TSHRCDC25BALDH1A1CDC25ACDC25C
SCHEMBL954473 0.82 TSHR (0.59) TSHRCDC25BALDH1A1CDC25ACDC25C
SCHEMBL7741671 0.82 TSHR (0.59) TSHRCDC25BALDH1A1CDC25ACDC25C
SCHEMBL29583963 0.81 TSHR (0.47) TSHRALDH1A1HSD17B10CYP1A2CNR2
SCHEMBL2362495 0.81 TSHR (0.47) TSHRALDH1A1HSD17B10CYP1A2CNR2
SCHEMBL265052 0.81 TSHR (0.63) TSHRCDC25BALDH1A1CDC25ACDC25C
SCHEMBL408906 0.81 TSHR (0.74) TSHRCDC25BALDH1A1HSD17B10MAPT
SCHEMBL28307395 0.81 MAPT (0.49) ALDH1A1HSD17B10CNR2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115955853-B Organic light emitting diode and organic light emitting device including the same 乐金显示有限公司 2026-05-15 CN disclosed
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SITEONE THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-20230309373-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-09-28 US disclosed
US-20230309373-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-09-28 US disclosed
CN-116437680-A Organic light emitting diode and organic light emitting device including the same 乐金显示有限公司 2023-07-14 CN disclosed
CN-116390516-A Organic light emitting diode and organic light emitting device including the same 乐金显示有限公司 2023-07-04 CN disclosed
US-20230200207-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-06-22 US disclosed
US-20230148324-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-05-11 US disclosed
US-20230148324-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-05-11 US disclosed
US-20230132589-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-05-04 US disclosed
US-20090012138-A1 4-IMIDAZOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-08 US disclosed
US-20090012138-A1 4-IMIDAZOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-08 US disclosed
US-20090012138-A1 4-IMIDAZOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-08 US disclosed
WO-2009003867-A1 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-08 WO disclosed
EP-1981497-A2 USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-22 EP disclosed
US-20070197621-A1 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 US disclosed
US-20070197621-A1 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 US disclosed
US-20070197621-A1 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 US disclosed
WO-2007085557-A2 USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 WO disclosed
WO-2007085557-A2 USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834456-B2 11,13-modified saxitoxins for the treatment of pain SCN11A, SCN10A, CACNA1A TSHR 2253/4885CDC25B 3208/4885ALDH1A1 4050/4885
US-20090012138-A1 4-IMIDAZOLINES TAAR1, TAAR5, GPR119 TSHR 23/4885CDC25B 1297/4885ALDH1A1 612/4885
US-20230132589-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME PPOX, PER2, CRY1 TSHR 4473/4885CDC25B 892/4885ALDH1A1 462/4885
US-20070197621-A1 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives GPR119, PER2, MTNR1B TSHR 222/4885CDC25B 512/4885ALDH1A1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.